Company Overview
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing novel immunotherapies designed for the treatment of cancer, with a specific focus on pipeline products such as BDC-4182 which targets the tumor-associated antigen claudin 18.2 for gastric applications. The firm functions within the broader Healthcare sector and specifically the Biotechnology industry, positioning itself as an entity focused on advancing specialized therapeutic modalities rather than established pharmaceutical commodities. The company's current scale is defined by a market capitalization of $8.42M, annual revenue of $7.70M, and an employee count of 23 individuals. These financial metrics indicate that the company is a small-cap entity with limited market penetration relative to large-cap peers, suggesting a high-risk profile where limited revenue generation must support expensive research and development activities typical of clinical-stage biotechnology ventures.
Financial Health
The company reported total revenue of $7.70M over the trailing twelve months, yet recorded a net income of -$33,376,000 and an EBITDA of -$33,342,000, revealing a significant gap between top-line generation and bottom-line profitability driven by substantial operational expenses. This disparity between revenue and net income highlights a cost structure heavily weighted toward research, development, and general administrative costs that are not yet offset by commercial sales or licensing deals. Free cash flow stands at -$24,904,624, indicating that the company is burning cash faster than it is generating it from operations, which constrains its immediate financial flexibility and necessitates external capital raises to fund ongoing clinical trials. The gross margin is reported at -270.8%, the operating margin at -224.2%, and the profit margin at 0.0%, figures that collectively illustrate a business model currently unable to cover its direct costs of sales or operational overheads with profit. On the balance sheet, the company holds $27.50M in cash against $22.96M in debt, resulting in a debt-to-equity ratio of 86.62 which suggests a leveraged position relative to its equity base. Despite the leverage, the current ratio of 3.59 indicates a strong short-term liquidity position, meaning the company possesses sufficient current assets to cover its current liabilities many times over. However, the return on equity is -79.7% and the return on assets is -27.7%, metrics that reveal management has not yet achieved positive returns on the capital deployed, reflecting the early-stage nature of the asset and the challenges of monetizing the pipeline before commercial launch.
Valuation Assessment
The P/E ratio (TTM) is N/A due to negative earnings, while the forward P/E is -0.18, a metric that implies the market is pricing in significant future earnings volatility or a lack of immediate profitability rather than a standard growth trajectory. The price-to-book ratio stands at 0.32, indicating that the market values the company at significantly less than its book value, a common characteristic for biotechnology firms with substantial intangible assets that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 1.09 and an EV/EBITDA of -0.12 suggest that the market is valuing the company based on its sales potential rather than current earnings power, though the negative EV/EBITDA underscores the lack of earnings generation. The stock has traded between a 52-week low of $3.91 and a 52-week high of $9.66, and without the specific current share price, the exact percentage position relative to this range cannot be calculated, but the wide range reflects the inherent volatility of clinical-stage biotech equities. The beta value is 0.87, which indicates that the stock's price volatility is slightly lower than the broader market benchmark, suggesting it may not amplify market movements as aggressively as high-beta technology or small-cap stocks during periods of market stress.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, indicating that the company is either reporting its first commercial sales or has not maintained consistent growth rates over a comparable prior period, which implies earnings are not growing faster than revenue in a traditional sense but rather the business is in a transition phase. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute profits to shareholders but instead retains all earnings to reinvest into the development of its cancer immunotherapy pipeline. As a non-dividend payer, Bolt Biotherapeutics reinvests all available capital, including its cash reserves, directly into research, development, and clinical trial activities to advance its product candidates toward market approval. The overall growth and income profile is characterized by a lack of current profitability and dividend income, relying entirely on the potential future value of its pipeline and the successful commercialization of its novel immunotherapies for the treatment of cancer.